$Johnson & Johnson (JNJ.US)$ has been under pressure due to ...
$Johnson & Johnson(JNJ.US$ has been under pressure due to talc lawsuits alleging its talc products cause ovarian cancer. In May, the company proposed a $6.5 billion settlement to resolve these claims. Despite this, J&J remains a top dividend stock with a 3.37% yield and has increased its dividend for 62 consecutive years. It has a forward P/E ratio of 13.79 makes it undervalued compared to the broader market. However, the firm does have more than forty new products in late stage clinical trials that could inject life into the shares. The average of 23 one year analyst share price targets for the firm is $172.16, and the average share rating is Buy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
